Before Ozempic, Wegovy, Mounjaro and Zepbound, there was Lotte Bjerre Knudsen.
In the 1990s, the young scientist at the Danish drug company Novo Nordisk was trying to unlock the key to a new technology for treating Type 2 diabetes. To her bosses, Lotte’s project, which focused on a hormone called GLP-1, looked like a distraction.
But as Lotte fought to save her diabetes project from the chopping block, she couldn’t have imagined how much of an impact her breakthrough would have. Her work would pave the way for a hit drug called Ozempic. And it would unleash a new class of blockbuster drugs, pitting two companies in a race to become the world’s first trillion-dollar pharmaceutical company by market cap.
Listen to Part 1 of “Trillion Dollar Shot” now.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Inside the White House's Scramble to Avert a Bigger Middle East War
Donald Trump’s First Criminal Trial Is Underway
How Cyber Thieves Are Disrupting U.S. Goods
Think It’s Expensive to Buy a Home? Try Owning One.
Why the Fed Is Steering Away From Rate Cuts
Many Cities Fear the ‘Doom Loop.’ St. Louis is in One.
The Russian Military is Using Elon Musk’s Starlink
Can the WNBA Cash in on the Caitlin Clark Effect?
How Employer-Funded Child Care Can Work
What Arizona's Abortion Ban Means for the 2024 Election
Biden’s New Plan to Cancel Student Debt
Why No Labels’ Presidential Campaign Failed to Launch
Janet Yellen Has a Warning for China
The Failures Inside Boeing's 737 Factory
A Deadly Strike on Aid Workers in Gaza
The Battle Over Disney’s Board
Ryanair: Cheap, Cramped and Making Its CEO a Fortune
Six Days of Chaos at MGM’s Casinos
25 Years in Prison from “The Trial of Crypto’s Golden Boy”
Donald Trump’s Meme Stock Moment
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained